SMARCA5 and urinary bladder carcinoma: For instance, SMARCA5 can promote cell proliferation in bladder cancer and prostate cancer (Tan et al., 2019), suppress colorectal cancer progression (Miao et al., 2020), inhibit tumor metastasis in cervical cancer (Zhang X. et al., 2021) and inhibit cell proliferation, migration, and invasion in non-small cell lung cancer (Wang et al., 2019), and boost cell migration and invasion as well as inhibit cell apoptosis in bladder cancer (Kong et al., 2017; Tan et al., 2019).